| Potassium-wasting nephropathy secondary to chemotherapy simulating Bartter's syndrome. | |
| | |
MedLine Citation:
|
PMID: 6204737 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
A patient with a potassium wasting nephropathy secondary to chemotherapy simulating Bartter's syndrome is described. A 64-year-old woman with diffuse histiocytic lymphoma developed persistent hypokalemia following a course of Cytoxan (cyclophosphamide), Adriamycin (doxorubicin), vincristine, and prednisone (CHOP)-Bleo. The diagnosis of a functional Bartter's syndrome was concluded following evaluation of serial plasma renins, aldosterone levels, and urinary electrolytes. Evidence is suggestive that a subpopulation of patients receiving chemotherapy may develop a functional Bartter's syndrome, and it is important to consider this diagnosis in patients who develop hypokalemia subsequent to chemotherapy introduction. |
| | |
Authors:
|
I H Lieber; S D Stoneburner; M Floyd; W L McGuffin |
Related Documents
:
|
3862357 - Experimentally induced phenylbutazone toxicosis in ponies: description of the syndrome ... 3683687 - Mesangial iga nephropathy and idiopathic nephrotic syndrome. 4890207 - Nephrotic syndrome due to primary renal disease in adults: ii. a controlled trial of pr... 6507587 - Spontaneous nephrotic syndrome in a genetic rat model. 931377 - Epichloë typhina from toxic tall fescue grasses. 9934987 - Costello syndrome: report and review. |
Publication Detail:
|
Type: Case Reports; Journal Article |
Journal Detail:
|
Title: Cancer Volume: 54 ISSN: 0008-543X ISO Abbreviation: Cancer Publication Date: 1984 Sep |
Date Detail:
|
Created Date: 1984-09-06 Completed Date: 1984-09-06 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0374236 Medline TA: Cancer Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 808-10 Citation Subset: AIM; IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aldosterone
/
blood Antineoplastic Combined Chemotherapy Protocols / adverse effects*, therapeutic use Bartter Syndrome / blood, chemically induced*, urine Bleomycin / administration & dosage, adverse effects Cyclophosphamide / administration & dosage, adverse effects Diagnosis, Differential Doxorubicin / administration & dosage, adverse effects Female Humans Hyperaldosteronism / chemically induced* Hypokalemia / blood, chemically induced*, urine Lymphoma, Large B-Cell, Diffuse / blood, drug therapy, urine Magnesium / urine Middle Aged Prednisone / administration & dosage, adverse effects Renin / blood Vincristine / administration & dosage, adverse effects |
| Chemical | |
Reg. No./Substance:
|
0/CHOP-B protocol; 11056-06-7/Bleomycin; 23214-92-8/Doxorubicin; 50-18-0/Cyclophosphamide; 52-39-1/Aldosterone; 53-03-2/Prednisone; 57-22-7/Vincristine; 7439-95-4/Magnesium; EC 3.4.23.15/Renin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Radiation therapy in primary carcinoma of the female urethra. II. An update on results.
Next Document: Correlation between response to cisplatinum-combination chemotherapy and subsequent radiotherapy in ...